Semaglutide Not Linked to Pancreatic Cancer, Study Finds

Study Design and Data Sources

A recent analysis of national health registries from Denmark, Sweden, and Norway shows no association between the diabetes drug semaglutide and pancreatic cancer. The findings will be presented at the European Association for the Study of Diabetes (EASD) meeting in Milan from September 28 to October 2, 2026.

Researchers examined data from over 200,000 patients who received semaglutide between 2015 and 2024. They matched users with non‑users on age, sex, and other risk factors. The study tracked cancer diagnoses for up to ten years after first prescription. No statistically significant increase in pancreatic cancer rates was detected among semaglutide users.

The analysis used comprehensive, nationwide registries that record prescription fills, hospital admissions, and cancer diagnoses. Denmark contributed 85,000 participants, Sweden 65,000, and Norway 50,000. Follow‑up began at the first semaglutide fill and continued until the end of 2024 or until a cancer diagnosis occurred. Researchers applied Cox proportional hazards models to estimate risk. Adjustments were made for diabetes duration, body mass index, smoking status, and other medications. The study’s robustness is enhanced by the large sample size and the long observation period.

Implications for Diabetes Care

Clinicians have worried that GLP‑1 receptor agonists might raise pancreatic cancer risk. This new evidence alleviates those concerns for semaglutide. Patients with type 2 diabetes who need weight loss or improved glycaemic control can consider semaglutide without added cancer risk. The findings also support ongoing drug approvals in the European Union and the United States. However, experts advise continued vigilance, as rare adverse events may still emerge with wider use.

The study’s authors note that the absence of a signal does not prove safety in all populations, but it strengthens the drug’s safety profile. They recommend that future research monitor other potential long‑term effects, such as gastrointestinal complications or endocrine disorders. The data also underscore the value of national registries for pharmacovigilance.

The EASD conference will feature a live discussion on these results. Attendees will hear how the data were collected, the statistical methods employed, and the clinical implications for patients and prescribers. The presentation aims to inform guidelines and reassure patients who have expressed anxiety about GLP‑1 therapies.

Frequently Asked Questions

Q1: Does this study mean semaglutide is safe for everyone? A1: The study shows no link to pancreatic cancer in the examined populations. It does not cover all possible side effects or rare events, so patients should discuss individual risks with their doctors.

Q2: How long were patients followed in the study? A2: Follow‑up lasted up to ten years after the first prescription in each country, providing a long window for cancer detection.

Q3: Will this affect drug approvals? A3: The findings support current approvals and may encourage broader use. Regulators may still require additional post‑marketing studies for comprehensive safety monitoring.